A claim about fat metabolism does not establish selective removal of fat from a chosen body area. AOD-9604 discussions frequently move between weight loss, body-fat percentage and stubborn abdominal fat as if those were the same endpoint.
The measurement must match the promise
Scale weight includes more than fat. A body-composition estimate is another measure, and regional fat distribution is a further question. A change in one cannot automatically prove improvement in all the others.
The FDA's review discusses the human obesity trials and their limitations. The disappointing main weight-loss result cannot be converted into a demonstrated regional-fat success simply by changing the wording of the claim.
Animal metabolism is not a spot-reduction trial
The mouse research addresses experimental lipid metabolism. It does not establish that a person can direct AOD-9604's effect toward a particular deposit of fat.
Likewise, administering something near an area does not by itself prove a local clinical effect. A regional claim needs evidence that measures that region and compares the intervention appropriately.
A photograph, waist measurement or consumer-scale trend can change for several reasons and does not isolate a peptide's contribution in an uncontrolled personal experiment.
Keep the clinical goal clear
If the concern is a medical condition, a clinician should identify the relevant diagnosis and outcome. If the concern is cosmetic, that does not remove the need to assess risk and avoid unsupported treatment claims.
A useful article should explain whether a cited study measured total mass, fat mass, regional tissue or a laboratory marker. It should not allow the phrase stubborn fat to stand in for all of them.
The evidence cited here does not establish targeted abdominal-fat treatment with a research AOD-9604 product. It provides no injection-site strategy or regimen. The meaningful next question is what evidence supports the exact outcome being sought, not how persuasive a fat-burning description sounds.